Compare AbCellera Biologics Inc (ABCL) vs Amplitude Inc (AMPL) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Amplitude (AMPL) trades at $9.16, up 3.62% on the day, with a bullish technical signal from moving averages. Revenue growth is solid at $343M in 2025, but net losses persist at -$89M. Analyst consensus is 66.7% buy with a $9.00 target. Recent news highlights improving fundamentals but also legal investigations.

The outlook is mixed: strong revenue growth and analyst support offer upside, but profitability challenges and legal risks pose headwinds. Investors should weigh the bullish technicals and growth potential against ongoing losses and regulatory scrutiny for balanced risk-reward assessment.